Krishna Institute of Medical Sciences Ltd
KIMSKrishna Institute of Medical Sciences Ltd's price has outrun its earnings. +6.4% in a year against EPS −37.3% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +6.4% in a year while annual EPS moved −37.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 100th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −68.9% year on year, and 163% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Krishna Institute of Medical Sciences Ltd trades at ₹805, in a confirmed uptrend and 12 weeks into that stage. That is +11.8% against its own 200-day average. It sits at 83% of a 52-week range of ₹582 to ₹851. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹805 it trades +11.8% versus its 200-day average and sits at 83% of its 52-week range (₹582–₹851).
Against the market, two honest reads. Cumulative: over the last 5.1 years the stock moved +295% while the NIFTY 500 moved +72% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Krishna Institute of Medical Sciences Ltd trades at 136.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 49.6×, measured across 5.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 136.0× is about the priciest it has ever traded, against a long-run median of 49.6× measured over 5.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −37.3% against a +6.4% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +27.3%/yr price move, ~+3.5%/yr came from earnings growth and ~+23.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 27% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Krishna Institute of Medical Sciences Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 9.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +28.7% | +21.1% | +24.0% | +22.5% |
| Profit | −41.7% | −12.9% | +3.4% | +24.1% |
| EPS | −37.3% | −10.5% | +3.0% | +23.0% |
| Share price | +6.4% | +27.8% | +27.3% | — |
4-Factor Sector Score
39.4/100 — rank 15 of 19 in Hospitals · 78% evidence confidence
Krishna Institute of Medical Sciences Ltd scores 39.4 out of 100 against the 19 companies it is compared with in Hospitals, ranking 15. Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 10.4 + 9.2 + 5.5 + 14.3 = 39.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Krishna Institute of Medical Sciences Ltd reported ₹1,075 Cr of revenue in the Mar 26 quarter, +34.9% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 22.5% a year. The last full year, FY26, came in at ₹3,905 Cr. The last four reported quarters add to ₹3,906 Cr.
FY26 revenue came in at ₹3,905 Cr (+28.7% on the year), capping 10 years at 22.5% compound. The latest quarter (Mar 26) printed ₹1,075 Cr, +34.9% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +28.6% growth against the decade's 22.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +28.7% over the last 4 quarters against +25.0%/yr over the last 8 — accelerating; TTM profit −41.5% vs −15.3%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Krishna Institute of Medical Sciences Ltd's operating margin is 19.0% in the Mar 26 quarter, −6.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 9.0% to 32.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 19.0%, −6.0 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 9.0%–32.0%.
🚨 Why the margin moved: operating margin went −5.6 pp year on year while gross margin went −0.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Krishna Institute of Medical Sciences Ltd earned ₹33.0 Cr of net profit in the Mar 26 quarter, −68.9% year on year. Full-year FY26 profit was ₹242 Cr. The 10-year compound rate is 24.1%. That is 3.1% of the quarter's revenue. The same quarter a year earlier earned ₹106 Cr.
Mar 26 profit was ₹33.0 Cr, −68.9% year on year. On the full year, FY26 printed ₹242 Cr (−41.7%), and the 10-year compound rate is 24.1%.
🚨 Why profit moved: revenue contributed +34.9% and the margin −6.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −40.9% vs revenue +28.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 163% of Krishna Institute of Medical Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹511 Cr of operating cash against ₹242 Cr of profit. After ₹2,037 Cr of capital spending, ₹−1,526 Cr was left as free cash.
FY26: operating cash of ₹511 Cr against reported profit of ₹242 Cr, leaving free cash of ₹−1,526 Cr after ₹2,037 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 163% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 163%: the cash cycle stretched 56 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 7.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Krishna Institute of Medical Sciences Ltd's cash conversion cycle runs −50 days in FY26, up from −106 days in FY21. Capital spending ran ₹4,680 Cr over the last 3 years. At FY26 sales of ₹3,905 Cr each day of that cycle holds about ₹10.7 Cr, so roughly ₹−535 Cr sits inside the business at any moment.
FY26: debtors at 52 days, inventory at 44 days — roughly 1.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −50 days, looser than FY21's −106.
The full loop: cash goes out to suppliers and production on day 0; stock waits 44 days to sell; customers pay about 52 days after that; and suppliers themselves are paid at 146 days — netting out to the −50-day cycle.
In money terms: at FY26 sales of ₹3,905 Cr, each day of the cycle holds about ₹10.7 Cr — so the −50-day loop keeps roughly ₹−535 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹4,680 Cr over the last 3 fiscal years against ₹607 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹606 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Krishna Institute of Medical Sciences Ltd earns a ROCE of 9% in FY26. That is up from a trough of 5% in FY19. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 6.2% net margin on 0.50× asset turns.
FY26 ROCE is 9%, recovered from a FY19 trough of 5% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 6.2% net margin × 0.50× asset turns × 3.45× balance-sheet leverage ≈ 10.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 27% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Krishna Institute of Medical Sciences Ltd carries ₹4,253 Cr of borrowings against ₹2,247 Cr of equity in FY26, a debt-to-equity of 1.89. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹316 Cr to ₹4,253 Cr. Capital spending ran ₹4,680 Cr across the last 3 of those years.
FY26: borrowings of ₹4,253 Cr against equity of ₹2,247 Cr — a debt-to-equity of 1.89. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹316 Cr to ₹4,253 Cr while capital spending ran ₹4,680 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 27% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 6.3 points of Krishna Institute of Medical Sciences Ltd over 8 quarters, the biggest move on the register. That takes promoters to 32.5% of the company. Foreign institutions moved −3.1 points over the same window, to 14.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −6.3 points over 8 quarters to 32.5%; Foreign institutions: −3.1 points over 8 quarters to 14.8%; Domestic institutions: +2.3 points over 8 quarters to 34.4%.
Why the register moved: rotation — foreign institutions −3.1 points against domestic institutions +2.3 points over 8 quarters, with promoters −6.3 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Krishna Institute of Medical Sciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1KMC Speciality Hospitals (India) Ltd524520 | 82.1/100Sector-leading setup78% evidence | LEADER | 30.8/35 Revenue 32.5% · PAT 100% · OPM change 6 pp 83% evidence | 20.6/25 ROCE 26% · OPM 31% 76% evidence | 11.2/20 P/E 44.5× · PEG — 50% evidence | 19.5/20 RS sector 34% · RS bench 44.3% · 1Y 97.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 20.6 + 11.2 + 19.5 = 82.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Artemis Medicare Services LtdARTEMISMED | 67.9/100Favorable setup96% evidence | LEADER | 24.4/35 Revenue 15.5% · PAT 24.1% · OPM change 3 pp 88% evidence | 12.0/25 ROCE 14.6% · OPM 18% 100% evidence | 14.4/20 P/E 44.6× · PEG 1.09 100% evidence | 17.1/20 RS sector 8.2% · RS bench 17.1% · 1Y 24.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 12 + 14.4 + 17.1 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sakar Healthcare LtdSAKAR | 67.6/100Favorable setup87% evidence | LEADER | 32.2/35 Revenue 43.9% · PAT 71.4% · OPM change 5 pp 95% evidence | 11.0/25 ROCE 12.7% · OPM 29% 95% evidence | 6.9/20 P/E 54.6× · PEG — 50% evidence | 17.5/20 RS sector 57% · RS bench 68.5% · 1Y 144.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 11 + 6.9 + 17.5 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Apollo Hospitals Enterprise LtdAPOLLOHOSP | 67.1/100Favorable setup78% evidence | LEADER | 23.6/35 Revenue 15.8% · PAT 33% · OPM change 1 pp 83% evidence | 15.4/25 ROCE 17.9% · OPM 15% 76% evidence | 12.6/20 P/E 65.8× · PEG — 50% evidence | 15.5/20 RS sector 5.2% · RS bench 13.7% · 1Y 19.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 15.4 + 12.6 + 15.5 = 67.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rainbow Childrens Medicare LtdRAINBOW | 58.0/100Mixed-positive evidence100% evidence | BREAKING OUT | 18.0/35 Revenue 18.3% · PAT 12.4% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 17.4% · OPM 29% 100% evidence | 7.3/20 P/E 54.1× · PEG 2.97 100% evidence | 15.6/20 RS sector 4% · RS bench 12.4% · 1Y -2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 17.1 + 7.3 + 15.6 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Max Healthcare Institute LtdMAXHEALTH | 57.8/100Mixed-positive evidence90% evidence | TURNING | 25.1/35 Revenue 19.1% · PAT 34% · OPM change 1 pp 88% evidence | 15.8/25 ROCE 14.7% · OPM 28% 100% evidence | 10.8/20 P/E 72.1× · PEG 1.73 100% evidence | 6.1/20 RS sector -7.9% · RS bench 0.1% · 1Y -14.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 25.1 + 15.8 + 10.8 + 6.1 = 57.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.9% and the one-year return is -14.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Kovai Medical Center & Hospital LtdKOVAI | 54.6/100Mixed-positive evidence96% evidence | FADING | 17.8/35 Revenue 15.8% · PAT 16.2% · OPM change -1 pp 88% evidence | 21.3/25 ROCE 22.6% · OPM 27% 100% evidence | 10.4/20 P/E 26.3× · PEG 1.51 100% evidence | 5.1/20 RS sector -7.4% · RS bench 0.2% · 1Y -3.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 21.3 + 10.4 + 5.1 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Dr Agarwals Eye Hospital LtdDRAGARWQ | 54.3/100Mixed-positive evidence90% evidence | ASLEEP | 19.6/35 Revenue 18.6% · PAT 27.8% · OPM change -4 pp 88% evidence | 16.8/25 ROCE 17.4% · OPM 28% 100% evidence | 10.6/20 P/E 34.6× · PEG 1.72 100% evidence | 7.3/20 RS sector -4% · RS bench -1% · 1Y 13.4%4 of 7 weeks ahead 70% evidence |
| Exact sum: 19.6 + 16.8 + 10.6 + 7.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Global Health LtdMEDANTA | 54.1/100Mixed-positive evidence100% evidence | LEADER | 12.3/35 Revenue 21.3% · PAT 3.4% · OPM change -2 pp 100% evidence | 13.9/25 ROCE 17.1% · OPM 22% 100% evidence | 11.3/20 P/E 66× · PEG 1.11 100% evidence | 16.6/20 RS sector 4.5% · RS bench 13% · 1Y 6.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 13.9 + 11.3 + 16.6 = 54.1 · Decision use: Price leads the evidence: RS versus the benchmark is 13%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Indraprastha Medical Corporation LtdINDRAMEDCO | 52.2/100Mixed-positive evidence90% evidence | ASLEEP | 12.4/35 Revenue 9.3% · PAT 13.7% · OPM change -1 pp 88% evidence | 18.6/25 ROCE 35.8% · OPM 17% 100% evidence | 17.2/20 P/E 18.3× · PEG 0.92 100% evidence | 4.0/20 RS sector -8.4% · RS bench -17.3% · 1Y -20.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 18.6 + 17.2 + 4 = 52.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11Fortis Healthcare LtdFORTIS | 50.2/100Mixed-positive evidence78% evidence | FADING | 23.6/35 Revenue 17.3% · PAT 31.5% · OPM change 1 pp 83% evidence | 12.8/25 ROCE 13.4% · OPM 23% 76% evidence | 9.0/20 P/E 67.5× · PEG — 50% evidence | 4.8/20 RS sector -7.3% · RS bench 0.2% · 1Y 11.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 12.8 + 9 + 4.8 = 50.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.3% and the one-year return is 11.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Yatharth Hospital & Trauma Care Services LtdYATHARTH | 48.2/100Mixed-negative evidence78% evidence | FADING | 19.5/35 Revenue 36.1% · PAT 31.5% · OPM change -2 pp 83% evidence | 11.7/25 ROCE 12.4% · OPM 23% 76% evidence | 8.8/20 P/E 45× · PEG — 50% evidence | 8.2/20 RS sector 0.2% · RS bench 8.1% · 1Y 30.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 11.7 + 8.8 + 8.2 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13GPT Healthcare LtdGPTHEALTH | 47.9/100Mixed-negative evidence70% evidence | TURNING | 10.3/35 Revenue 16% · PAT -14% · OPM change -2 pp 83% evidence | 18.5/25 ROCE 19.9% · OPM 18% 95% evidence | 11.2/20 P/E 32.5× · PEG — 15% evidence | 7.9/20 RS sector -15.8% · RS bench 17.9% · 1Y 5.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 10.3 + 18.5 + 11.2 + 7.9 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Aster DM Quality Care LtdASTERDM | 39.4/100Mixed-negative evidence96% evidence | LEADER | 12.6/35 Revenue 12.2% · PAT -80% · OPM change 1 pp 88% evidence | 9.8/25 ROCE 11.4% · OPM 19% 100% evidence | 1.5/20 P/E 176× · PEG 3.07 100% evidence | 15.5/20 RS sector 10.8% · RS bench 19.6% · 1Y 41.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.8 + 1.5 + 15.5 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Krishna Institute of Medical Sciences Ltdthis pageKIMS | 39.4/100Mixed-negative evidence78% evidence | LEADER | 10.4/35 Revenue 28.7% · PAT -41.5% · OPM change -6 pp 83% evidence | 9.2/25 ROCE 9.3% · OPM 19% 76% evidence | 5.5/20 P/E 136× · PEG — 50% evidence | 14.3/20 RS sector 3.7% · RS bench 12% · 1Y 5.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 9.2 + 5.5 + 14.3 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Narayana Hrudayalaya LtdNH | 39.3/100Mixed-negative evidence87% evidence | TURNING | 12.6/35 Revenue 59.6% · PAT 3.8% · OPM change -5 pp 100% evidence | 11.6/25 ROCE 15.5% · OPM 17% 100% evidence | 6.1/20 P/E 48.1× · PEG 3 65% evidence | 9.0/20 RS sector -4.3% · RS bench 9.2% · 1Y 1.9%5 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 11.6 + 6.1 + 9 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Healthcare Global Enterprises LtdHCG | 35.9/100Mixed-negative evidence65% evidence | TURNING | 13.1/35 Revenue 14.5% · PAT -53.4% · OPM change 1.1 pp 83% evidence | 7.4/25 ROCE 8.3% · OPM 19.2% 76% evidence | 8.5/20 P/E 349× · PEG — 15% evidence | 6.9/20 RS sector -8.1% · RS bench 3.4% · 1Y 18.5%8 of 10 weeks ahead 70% evidence |
| Exact sum: 13.1 + 7.4 + 8.5 + 6.9 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Shalby LtdSHALBY | 30.7/100Adverse evidence69% evidence | ASLEEP | 15.6/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 62% evidence | 2.5/25 ROCE 6.5% · OPM 10% 95% evidence | 9.1/20 P/E 46.6× · PEG — 50% evidence | 3.5/20 RS sector -28.4% · RS bench -14.9% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 15.6 + 2.5 + 9.1 + 3.5 = 30.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jupiter Life Line Hospitals LtdJLHL | 29.8/100Adverse evidence100% evidence | BASING | 8.4/35 Revenue 14.7% · PAT -3.1% · OPM change -3 pp 100% evidence | 10.5/25 ROCE 14.8% · OPM 19% 100% evidence | 6.4/20 P/E 56.9× · PEG 3.44 100% evidence | 4.5/20 RS sector -74.8% · RS bench 17.9% · 1Y -77.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 8.4 + 10.5 + 6.4 + 4.5 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Krishna Institute of Medical Sciences Ltd's share price today?
Krishna Institute of Medical Sciences Ltd trades at ₹805, +6.4% over the past year. The company is valued at ₹33,798 Cr. The stock sits at 83% of its 52-week range of ₹582–₹851, +11.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 31 July 2026.
What were Krishna Institute of Medical Sciences Ltd's latest quarterly results?
Krishna Institute of Medical Sciences Ltd reported revenue of ₹1,075 Cr and net profit of ₹33.0 Cr for the Mar 26 quarter. Revenue rose 34.9% and profit fell 68.9% year on year. Earnings per share were ₹1.06. The operating margin was 19.0%, 6.0 pp lower than a year earlier. — as of 31 July 2026.
What is Krishna Institute of Medical Sciences Ltd's revenue?
Krishna Institute of Medical Sciences Ltd reported revenue of ₹1,075 Cr in the Mar 26 quarter, +34.9% year on year. For the full FY26 fiscal year, revenue was ₹3,905 Cr (+28.7%). Over the last 10 years revenue compounded at 22.5% a year. — as of 31 July 2026.
What is Krishna Institute of Medical Sciences Ltd's profit?
Krishna Institute of Medical Sciences Ltd earned ₹33.0 Cr of net profit in the Mar 26 quarter, −68.9% year on year. Full-year FY26 profit was ₹242 Cr. The operating margin ran 19.0% in the latest quarter. — as of 31 July 2026.
What is Krishna Institute of Medical Sciences Ltd's market cap?
Krishna Institute of Medical Sciences Ltd's market capitalisation is ₹33,798 Cr at a share price of ₹805. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Krishna Institute of Medical Sciences Ltd's P/E ratio?
Krishna Institute of Medical Sciences Ltd trades at a P/E of 136.0×, at the 100th percentile of its own 5-year range, against a long-run median of 49.6×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Krishna Institute of Medical Sciences Ltd pay a dividend?
No — Krishna Institute of Medical Sciences Ltd has recorded a dividend payout of 0% of profit in each of its last 11 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Krishna Institute of Medical Sciences Ltd overvalued?
On its own history, Krishna Institute of Medical Sciences Ltd looks expensive against its own history: its P/E of 136.0× sits at the 100th percentile of its 5-year range (long-run median 49.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Krishna Institute of Medical Sciences Ltd growing?
Not right now — Krishna Institute of Medical Sciences Ltd's latest numbers are shrinking: latest-quarter revenue +34.9% year on year, profit −68.9%, and the margin −6.0 pp at 19.0%. The 10-year compound rates are 22.5% (revenue) and 24.1% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Krishna Institute of Medical Sciences Ltd performing?
Krishna Institute of Medical Sciences Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 34.9% and profit fell 68.9% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. — as of 31 July 2026.
What stage is Krishna Institute of Medical Sciences Ltd in?
Mixed — no clean majority across the growth curves, ROCE slipping at 9.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +34.9% latest, profit growth −68.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Krishna Institute of Medical Sciences Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +11.8% versus its 200-day average and at 83% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Krishna Institute of Medical Sciences Ltd beating the market?
Not lately — on a trailing-13-week view Krishna Institute of Medical Sciences Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.1 years the stock moved +295% against the NIFTY 500's +72% — ahead of the index over the full window. — as of 31 July 2026.
Will Krishna Institute of Medical Sciences Ltd's share price go up?
This page publishes no price forecast for Krishna Institute of Medical Sciences Ltd. What it measures instead: the share price is ₹805, the price is in a confirmed uptrend 12 weeks in. Its P/E of 136.0× sits at the 100th percentile of its own 5-year range. — as of 31 July 2026.
Who owns Krishna Institute of Medical Sciences Ltd?
Promoters hold 32.5% of Krishna Institute of Medical Sciences Ltd, foreign institutions 14.8%, domestic institutions 34.4% and the public 18.3% (latest quarter). The biggest move on the register over the last two years: Promoters cut 6.3 points over 8 quarters. — as of 31 July 2026.
Does Krishna Institute of Medical Sciences Ltd have too much debt?
It carries real leverage — Krishna Institute of Medical Sciences Ltd's debt-to-equity is 1.89, and operating profit covers the interest bill 4×. FY26 borrowings were ₹4,253 Cr against equity of ₹2,247 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Krishna Institute of Medical Sciences Ltd's capex?
Krishna Institute of Medical Sciences Ltd spent ₹4,680 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹2,037 Cr, with ₹606 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Krishna Institute of Medical Sciences Ltd's cash flow?
Krishna Institute of Medical Sciences Ltd generated ₹511 Cr of operating cash flow in FY26 and ₹−1,526 Cr of free cash flow after ₹2,037 Cr of capital spending. Reported profit that year was ₹242 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Krishna Institute of Medical Sciences Ltd's profit real cash?
Yes — over the last 3 fiscal years, 163% of Krishna Institute of Medical Sciences Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹511 Cr against reported profit of ₹242 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Krishna Institute of Medical Sciences Ltd in its business cycle?
Krishna Institute of Medical Sciences Ltd's FY26 operating margin was 21.0%, against a 11-year band of 9.0%–32.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 19.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Krishna Institute of Medical Sciences Ltd story?
The sharpest disagreement: the price moved +6.4% in a year while annual EPS moved −37.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Krishna Institute of Medical Sciences Ltd a stock worth studying right now?
This is not investment advice. The machine read: Krishna Institute of Medical Sciences Ltd's price has outrun its earnings. +6.4% in a year against EPS −37.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.